Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 112 (LINC00112) is a member of the long intergenic non-coding RNA (lincRNA) family, defined as transcripts longer than 200 nucleotides that do not code for proteins and do not overlap annotated protein-coding genes[1]. LincRNAs as a class are increasingly recognized for diverse regulatory functions, including chromatin remodeling, transcriptional and post-transcriptional gene regulation, and cellular homeostasis[3][5]. While some lincRNAs have been linked to disease processes such as cancer, cardiovascular, and neurodegenerative diseases, there is currently no direct evidence establishing LINC00112 itself as a validated therapeutic target, nor are there known drugs or biomarker functions specific to LINC00112[1]. LINC00112 may be studied in certain molecular or functional genomics projects, but its individual functional roles remain largely uncharacterized.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 112 (LINC00112).